An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Trial Profile

An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Diffuse large B cell lymphoma; Kaposi's sarcoma
  • Focus Adverse reactions
  • Sponsors Apogee Biotechnology Corporation; RedHill Biopharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 New indication 'kaposi sarcoma' has been added and changes in title, endpoints, patient inclusion criteria also.
    • 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top